-
Je něco špatně v tomto záznamu ?
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort
O. Fursa, W. Bannister, B. Neesgaard, D. Podlekareva, J. Kowalska, T. Benfield, J. Gerstoft, J. Reekie, LD. Rasmussen, I. Aho, G. Guaraldi, T. Staub, JM. Miro, JM. Laporte, D. Elbirt, T. Trofimova, D. Sedlacek, R. Matulionyte, C. Oprea, E....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
PubMed
38433476
DOI
10.1111/hiv.13620
Knihovny.cz E-zdroje
- MeSH
- COVID-19 * epidemiologie diagnóza MeSH
- dospělí MeSH
- HIV infekce * farmakoterapie epidemiologie MeSH
- hospitalizace * statistika a číselné údaje MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- počet CD4 lymfocytů MeSH
- rizikové faktory MeSH
- SARS-CoV-2 * MeSH
- senioři MeSH
- testování na COVID-19 statistika a číselné údaje metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described. METHODS: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive. RESULTS: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm3, and those with previous cardiovascular disease or malignancy were significantly more likely to have been tested, as were people with HIV in 2021 compared with those in 2020. Overall, 390 people with HIV (4.3%, 95% CI 3.9-4.8) tested positive (range: 2.6% in Northern to 7.1% in Southern Europe), and the odds of testing positive were higher in all regions than in Northern Europe and in 2021 than in 2020. In total, 64 people with HIV (0.7%, 95% CI 0.6-0.9) were hospitalized, of whom 12 died. Compared with 2020, the odds of positive testing decreased in all regions in 2021, and the associations with cardiovascular disease, malignancy, and use of tenofovir disoproxil fumarate disappeared in 2021. Among study participants, 58.9% received a COVID-19 vaccine (range: 72.0% in Southern to 14.8% in Eastern Europe). CONCLUSIONS: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.
Allergy Immunology and HIV Unit Kaplan Medical Center Rehovot Israel
Centre Hospitalier de Luxembourg Service des Maladies Infectieuses Luxembourg City Luxembourg
Centre of Excellence for Health Immunity and Infections Rigshospitalet Copenhagen Denmark
CIBERINFEC Instituto de Salud Carlos 3 Madrid Spain
Department of Adults' Infectious Diseases Medical University of Warsaw Warsaw Poland
Department of Infectious Diseases Odense University Hospital Odense Denmark
Department of Infectious Diseases Rigshospitalet Copenhagen Denmark
Division of Infectious Diseases Helsinki University Hospital Helsinki Finland
Hospital Universitario de Alava Vitoria Gasteiz Spain
Infectious Diseases Clinic Clinical Center University of Sarajevo Sarajevo Bosnia and Herzegovina
Infectious Diseases Service Hospital Clínic IDIBAPS University of Barcelona Barcelona Spain
Modena HIV Cohort Università degli Studi di Modena Modena Italy
Novgorod Centre for AIDS prevention and control Veliky Novgorod Russian Federation
UCL Centre for Clinical Research Epidemiology Modelling and Evaluation London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013767
- 003
- CZ-PrNML
- 005
- 20240905133856.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/hiv.13620 $2 doi
- 035 __
- $a (PubMed)38433476
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Fursa, O $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000215969880
- 245 10
- $a SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort / $c O. Fursa, W. Bannister, B. Neesgaard, D. Podlekareva, J. Kowalska, T. Benfield, J. Gerstoft, J. Reekie, LD. Rasmussen, I. Aho, G. Guaraldi, T. Staub, JM. Miro, JM. Laporte, D. Elbirt, T. Trofimova, D. Sedlacek, R. Matulionyte, C. Oprea, E. Bernasconi, V. Hadžiosmanović, A. Mocroft, L. Peters, EuroSIDA Study Group
- 520 9_
- $a BACKGROUND: Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described. METHODS: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive. RESULTS: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm3, and those with previous cardiovascular disease or malignancy were significantly more likely to have been tested, as were people with HIV in 2021 compared with those in 2020. Overall, 390 people with HIV (4.3%, 95% CI 3.9-4.8) tested positive (range: 2.6% in Northern to 7.1% in Southern Europe), and the odds of testing positive were higher in all regions than in Northern Europe and in 2021 than in 2020. In total, 64 people with HIV (0.7%, 95% CI 0.6-0.9) were hospitalized, of whom 12 died. Compared with 2020, the odds of positive testing decreased in all regions in 2021, and the associations with cardiovascular disease, malignancy, and use of tenofovir disoproxil fumarate disappeared in 2021. Among study participants, 58.9% received a COVID-19 vaccine (range: 72.0% in Southern to 14.8% in Eastern Europe). CONCLUSIONS: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a COVID-19 $x epidemiologie $x diagnóza $7 D000086382
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a HIV infekce $x farmakoterapie $x epidemiologie $7 D015658
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a SARS-CoV-2 $7 D000086402
- 650 12
- $a hospitalizace $x statistika a číselné údaje $7 D006760
- 650 _2
- $a testování na COVID-19 $x statistika a číselné údaje $x metody $7 D000086742
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a počet CD4 lymfocytů $7 D018791
- 650 _2
- $a senioři $7 D000368
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Bannister, W $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000347803364
- 700 1_
- $a Neesgaard, B $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Podlekareva, D $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark $u Department of Respiratory and Infectious Diseases, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000331870597
- 700 1_
- $a Kowalska, J $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000311664462
- 700 1_
- $a Benfield, T $u Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark
- 700 1_
- $a Gerstoft, J $u Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Reekie, J $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000185293559
- 700 1_
- $a Rasmussen, L D $u Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Aho, I $u Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Guaraldi, G $u Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy $1 https://orcid.org/0000000257243914
- 700 1_
- $a Staub, T $u Centre Hospitalier de Luxembourg, Service des Maladies Infectieuses, Luxembourg City, Luxembourg
- 700 1_
- $a Miro, J M $u Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain $u CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Laporte, J M $u Hospital Universitario de Alava, Vitoria-Gasteiz, Spain
- 700 1_
- $a Elbirt, D $u Allergy, Immunology and HIV Unit, Kaplan Medical Center, Rehovot, Israel
- 700 1_
- $a Trofimova, T $u Novgorod Centre for AIDS prevention and control, Veliky Novgorod, Russian Federation
- 700 1_
- $a Sedlacek, D $u Department of Infectious Diseases and Travel Medicine, Medical Faculty and Teaching Hospital Plzen, Charles University Prague, Plzen, Czech Republic
- 700 1_
- $a Matulionyte, R $u Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $u Vilnius University Hospital, Vilnius, Lithuania
- 700 1_
- $a Oprea, C $u Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Bernasconi, E $u Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland
- 700 1_
- $a Hadžiosmanović, V $u Infectious Diseases Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
- 700 1_
- $a Mocroft, A $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark $u UCL Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, UK
- 700 1_
- $a Peters, L $u Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark
- 710 2_
- $a EuroSIDA Study Group
- 773 0_
- $w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 25, č. 6 (2024), s. 711-724
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38433476 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133849 $b ABA008
- 999 __
- $a ok $b bmc $g 2143524 $s 1225633
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 25 $c 6 $d 711-724 $e 20240303 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
- LZP __
- $a Pubmed-20240725
